bevacizumab
roche
['crcsm', ' bev ', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
1l folfiri+/-bev better than folfox+/-bev in kras g12c mcrc patients? 12- 18- 24- month pfs rates were 48, 43 &amp; 32% and 46, 18 and 5% for folfiri+/- bev and folfox +/- bev respectively..
curious if others have seen similar trends?
#crcsm #esmo22 #oncoalert 
Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology